Ang Peng Tiam

'We have yet to deploy it at the clinics. We plan to apply for its use when we have eligible patients,' says TalkMed

SINGAPORE (Apr 27): RHB is maintaining its “neutral” call on TalkMed Group with a lower target price of 70 cents from 72 cents previously after the group reported a weak 1Q18 set of financial results.  

SINGAPORE (Mar 28): TalkMed says its CEO, Dr Ang Peng Tiam, has resumed his medical duties at the company this week, effective March 25, following an eight-month suspension which began in Jul 2017.

SINGAPORE (Feb 21): RHB is maintaining its "neutral" call on TalkMed as CEO Dr Ang Peng Tiam is still serving his eight-month suspension, which started on Jul 25 2017 and is expected to be back on March 26 or towards the end of 1Q18.

SINGAPORE (Jan 8): CIMB is maintaining its “hold” call on TalkMed Group with a lower target price of 68 cents from 92 cents previously, after cutting FY17-19F earnings per share (EPS) estimates by 18-21% to factor anticipated earnings losses from the

SINGAPORE (Nov 8): RHB has downgraded its call on TalkMed Group to “neutral” from “buy” previously while raising its target price from 69 cents to 72 cents, which implies 29 times FY18F P/E.